v3.26.1
Stockholders’ Equity (Tables)
6 Months Ended
Jun. 30, 2026
Stockholders’ Equity [Abstract]  
Schedule of Warrant and Stock Option Grants with Time-Based Vesting

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the six months ended June 30, 2026 were:

 

    Warrant Grants     Stock Option Grants     Restricted Stock Units  
    Number of
shares
subject to
warrants
    Weighted-
average exercise
price per
share
    Number of
shares
subject to
options
    Weighted-
average exercise
price
per share
    Number of
shares
subject to
restricted
stock units
 
Balance at December 31, 2025     300,306     $ 12.95       -     $ -       678  
Granted     1,130,703       11.73       -       -       -  
Exercised     (278 )     11.71         -        -       -  
Cancelled/Expired     (34 )     10,800       -       -       -  
Balance at June 30, 2026     1,430,697     $ 11.73       -     $ -       678  
Exercisable at June 30, 2026     928,251     $ 11.73       -     $ -       678  

 

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the six months ended June 30, 2025 were:

 

    Warrant Grants     Stock Option Grants     Restricted
Stock
Units
 
    Number of
shares
subject to
warrants
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
options
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
restricted
stock units
 
Balance at December 31, 2024     49,533     $ 165.60        -     $  -       678  
Granted     194,400       73.80       -       -       -  
Exercised     -       -       -       -       -  
Cancelled/Expired     -       -       -       -       -  
Balance at June 30, 2025     243,932     $ 73.80       -     $ -       678  
Exercisable at June 30, 2025     161,265     $ 73.80       -     $ -       678  
Schedule of Company’s Outstanding Warrants

The Company’s outstanding warrants at June 30, 2026 are as follows:

 

Warrants Outstanding   Warrants Exercisable  
Exercise Price Range   Number Outstanding     Weighted Average Remaining Contractual
Life (in years)
    Weighted
Average Exercise Price
    Number Exercisable     Weighted Average Exercise Price     Intrinsic
Value
 
$11.71 - $14.06     1,430,697       3.31     $ 11.73       928,251     $ 11.73     $ -  

 

The Company’s outstanding warrants at June 30, 2025, are as follows:

 

Warrants Outstanding   Warrants Exercisable  
Exercise Price
Range
  Number
Outstanding
    Weighted Average
Remaining
Contractual Life
(in years)
    Weighted
Average
Exercise Price
    Number
Exercisable
    Weighted
Average
Exercise Price
    Intrinsic
Value
 
$63.00 - $10,800.00     243,932       4.31     $ 73.80       161,265     $ 73.80       1,206,830  
Schedule of Stock-based Compensation Expense

As of June 30, 2026 and December 31, 2025, there was no unrecognized expense for unvested stock options and restricted stock awards.

 

    For the Three Months Ended     For the Six Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Stock-based compensation expense   $ 3,735     $ -     $ 16,139     $ -  

 

 

Stock-based compensation expense categorized by the equity components for the three and six months ended June 30, 2026 and 2025 is as follows:

 

    For the Three Months Ended     For the Six Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Common stock   $ 3,735     $    -     $ 16,139     $       -  
Total   $ 3,735     $ -     $ 16,139     $ -